Breast Cancer

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.

Experts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.

Treatment with gedatolisib-based regimens led to significant PFS benefits vs alpelisib/fulvestrant in PIK3CA-mutant HR-positive advanced breast cancer.

The FDA approved Guardant360 CDx as a companion diagnostic for vepdegestrant in ER-positive advanced or metastatic breast cancer with ESR1 mutations.

The FDA cleared vepdegestrant in ER+ breast cancer with ESR1 mutations, ODAC voted on key questions in breast and prostate cancer, and more.

Read a refresh of the top FDA news in breast cancer from April 2026, including an ODAC decision and a breakthrough device designation.

The FDA approved vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least 1 line of endocrine therapy.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Megan Kruse, MD, discusses the evolving role of FES-PET/CT in breast cancer, particularly invasive lobular carcinoma.

The FDA ODAC voted against the clinical benefit of switching to camizestrant after the emergence of an ESR1 mutation in HR-positive breast cancer.

The April 30, 2026, FDA ODAC meeting will focus on data from SERENA-6 for camizestrant in hormone receptor–positive, ESR1-mutated advanced breast cancer.

Drs Nunnery and Kang discuss the rapidly evolving treatment paradigm for first-line metastatic TNBC, including the emergence of novel ADCs.

Rena D. Callahan, MD, discusses the clinical utility and shifting paradigms of oral SERDs for patients with ER-positive advanced breast cancer.

Rena D. Callahan, MD, discusses questions regarding treatment sequencing with CDK4/6 inhibitors and ADCs in hormone receptor–positive breast cancer.

Rena D. Callahan, MD, notes the implications of adding camizestrant to an aromatase inhibitor in ER-positive breast cancer with an emergent ESR1 mutation.

Frontline treatment with zovegalisib, atirmociclib, and fulvestrant yielded responses in pretreated, PI3Kα-mutated HR-positive metastatic breast cancer.

Breast cancer experts discuss nuances of using CDK4/6 inhibitors to treat patients with high-risk hormone receptor–positive, HER2-negative early disease.

The top 5 OncLive TV videos of the week cover insights in head and neck cancer, esophageal cancer, renal cell carcinoma, and breast cancer.

Rena D. Callahan, MD, discusses clinical considerations for CDK4/6 inhibitor–based regimens and oral SERDs in hormone receptor–positive breast cancer.

Rena D. Callahan, MD, discusses the implications of the NATALEE trial of adjuvant ribociclib plus endocrine therapy in HR-positive early breast cancer.

Experts from across oncology specialties highlight research being presented at the 2026 AACR Annual Meeting.

Drs Nunnery and Iyengar highlight the evolving integration of GLP-1 agonists into the breast cancer treatment armamentarium.